Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Fluidigm Corporation    FLDM

FLUIDIGM CORPORATION (FLDM)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/17/2018 04/18/2018 04/19/2018 04/20/2018 04/23/2018 Date
6.23(c) 6.13(c) 5.93(c) 6.12(c) 6.14(c) Last
99 305 114 796 100 284 133 141 110 087 Volume
+0.97% -1.61% -3.26% +3.20% +0.33% Change
More quotes
Financials (USD)
Sales 2018 110 M
EBIT 2018 -47,2 M
Net income 2018 -52,2 M
Debt 2018 -
Yield 2018 -
Sales 2019 123 M
EBIT 2019 -37,5 M
Net income 2019 -42,6 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 2,17x
Capi. / Sales2019 1,94x
Capitalization 238 M
More Financials
Company
Fluidigm Corp. engages in the development, manufacturing, and commercialization of life science tools for the life science and Ag-Bio industries.Its products include High Throughput Genomics, Single Cell Genomics, and Mass Cytometry.The company was founded by Stephen R. Quake & Gajus V. Worthington... 
More about the company
Surperformance© ratings of Fluidigm Corporation
Trading Rating : - Investor Rating :
More Ratings
Latest news on FLUIDIGM CORPORATION
04/23Brad Kreger Joins Fluidigm as Senior Vice President, Global Operations
GL
04/20FLUIDIGM : to Report Q1 2018 Financial Results and Host Conference Call
AQ
04/19Fluidigm to Report Q1 2018 Financial Results and Host Conference Call
GL
04/19FLUIDIGM : Patent Issued for Selection of Aptamers Based on Geometry (USPTO 9938..
AQ
04/13Fluidigm Introduces High-Parameter Maxpar Immune Monitoring Panel for Transla..
GL
04/13FLUIDIGM : Releases CFTR Next-Generation Sequencing Library Prep Assay for Use W..
AQ
04/12Fluidigm Releases CFTR Next-Generation Sequencing Library Prep Assay for Use ..
GL
03/20FLUIDIGM : Helios Mass Cytometer Maintenance Service Agreement
AQ
03/19FLUIDIGM CORP : Change in Directors or Principal Officers (form 8-K)
AQ
03/15FLUIDIGM : Patent Issued for Single-Cell Nucleic Acid Analysis (USPTO 9909179)
AQ
More news
Sector news : Medical Software & Technology Services
04/23EUROPE MARKETS : European Stocks Hit 10-week High As Rising Bond Yields Lift Fin..
DJ
04/23Siemens CEO says rail business performed well in Q2
RE
04/23ROYAL PHILIPS : Trade war worries Philips as it banks on China growth
RE
04/23ROYAL PHILIPS : Correction to Philips 1Q Earnings Story
DJ
04/23ROYAL PHILIPS : Philips sees negative effects from US-China trade war - CEO
RE
More sector news : Medical Software & Technology Services
Latest Tweets
04/23Brad Kreger Joins Fluidigm as Senior Vice President, Global Operations  
04/23$FLDM Brad Kreger Joins Fluidigm as Senior Vice President, Global Operations .. 
04/23Brad Kreger Joins Fluidigm as Senior Vice President, Global Operations  
04/21“Evangelicals have completely turned their political ethics on its head," sai..
73
04/20Fluidigm to Report Q1 2018 Financial Results and Host Conference Call  
More tweets
Qtime:153
News from SeekingAlpha
04/12Fluidigm launches new test for variants in CF gene; shares up 2% 
03/14DAILY INSIDER RATINGS ROUND UP 3/12/ : Nmfc, fldm, dfrg, scm, tsi, gogo, crvs, e.. 
03/02Predicting EPS Growth 
02/25WEEK 9 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
02/19WEEK 8 BREAKOUT FORECAST :   Short-Term Picks To Give You An Edge 
Chart FLUIDIGM CORPORATION
Duration : Period :
Fluidigm Corporation Technical Analysis Chart | FLDM | US34385P1084 | 4-Traders
Technical analysis trends FLUIDIGM CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 6,68 $
Spread / Average Target 8,7%
EPS Revisions
Managers
NameTitle
Stephen Christopher Linthwaite President, CEO, Chief Operating Officer & Director
Samuel D. Colella Chairman
Vikram Jog Chief Financial & Accounting Officer
Patrick Schwager Jones Independent Director
Gerhard F. Burbach Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FLUIDIGM CORPORATION3.90%238
VEEVA SYSTEMS INC31.78%10 373
ATHENAHEALTH, INC9.79%5 857
HEALTHEQUITY INC39.99%3 981
COTIVITI HOLDINGS INC7.58%3 247
ALLSCRIPTS HEALTHCARE SOLUTIONS INC-15.95%2 192